Treatment of pulmonary hypertension secondary to connective tissue diseases

Thorax

Volumn 54, Issue 3, 1999, Pages 273-277

  Sanchez, Olivier ^a   Humbert, Marc ^a   Sitbon, Olivier ^a   Simonneau, Gérald ^a  

^a HÔPITAL ANTOINE BÉCLÈRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; DIGITALIS; DIURETIC AGENT; IMMUNOSUPPRESSIVE AGENT; PROSTACYCLIN; VASODILATOR AGENT;

ALTITUDE; ANTICOAGULANT THERAPY; BATH; CONNECTIVE TISSUE DISEASE; EXERCISE; HEART LUNG TRANSPLANTATION; HEART OUTPUT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LUNG ARTERY PRESSURE; LUNG CIRCULATION; OXYGEN THERAPY; PREGNANCY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; SCLERODERMA;

EID: 0033048993     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thx.54.3.273     Document Type: Review

References (60)

1. Stupi AM, Steen VD, Owens GR, et al. Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis. Arthritis Rheum 1986;29:515-24.
2. Ungerer RG, Tashkin DP, Furst D, et al. Prevalence and clinical correlates of pulmonary arterial hypertension in progressive systemic sclerosis. Am J Med 1983;75:65-74.
3. Salerni R, Rodnan GP, Leon DF, et al. Pulmonary hypertension in the CREST syndrome variant of progressive systemic sclerosis (scleroderma). Ann Intern Med 1977;86:394-9.
4. Alpert MA, Goldberg SH, Singsen BH, et al. Cardiovascular manifestations of mixed connective tissue disease in adults. Circulation 1983;68:1182-93.
5. Hosoda Y, Suzuki Y, Takano M, et al. Mixed connective rissue disease with pulmonary hypertension: a clinical and pathological study. J Rheumatol 1987;14:826-30.
6. Sullivan WD, Hurst DJ, Harmon CE, et al. A prospective evaluation emphasizing pulmonary involvement in patients with mixed connective tissue disease. Medicine 1984;63:92-107.
7. Asherson RA, Higenbottam TW, Dinh Xuan AT, et al. Pulmonary hypertension in a lupus clinic: experience with twenty four patients. J Rheumatol 1990;17:1292-8.
8. Perez HD, Kramer N. Pulmonary hypertension in systemic lupus erythematosus: report of four cases and review of the literature. Semin Arthritis Rheum 1981;11:177-81.
9. Simonson JS, Schiller NB, Petri M, et al. Pulmonary hypertension in systemic lupus erythematosus. J Rheumatol 1989;16:918-25.
10. Quismorio FP, Sharma O, Koss M, et al. Immunopathologic and clinical studies in pulmonary hypertension associated with systemic lupus erythematosus. Semin Arthritis Rheum 1984;13:349-59.
11. Ray J, Sermer M. Systemic lupus erythematosus and pulmonary hypertension during pregnancy: report of a case fatality. Can J Cardiol 1996;12:753-6.
12. Rubin LA, Geran A, Rose TH, et al. A fatal pulmonary complication of lupus in pregnancy. Arthritis Rheum 1995;38:710-4.
13. Palevsky HI, Schloo BL, Pietra GG, et al. Primary pulmonary hypertension: vascular structure, morphometry, and responsiveness to vasodilator agents. Circulation 1989;80:1207-21.
14. Bjornsson J, Edwards WD. Primary pulmonary hypertension: a histopathologic study of 80 cases. Mayo Clin Proc 1985;60:16-25.
15. Fuster V, Steele PM, Edwards WD, et al. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 1984;70:580-7.
16. Rich S, Kaufman E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992;327:76-81.
17. Naeye RL. Pulmonary vascular lesions in systemic scleroderma. Dis Chest 1963;44:374-80.
18. Bunch TW, Tancredi RG, Lie JT. Pulmonary hypertension in polymyositis. Chest 1981;79:105-7.
19. Balagopal VP, Da Costa P, Greenstone MA. Fatal pulmonary hypertension and rheumatoid vasculitis. Eur Respir J 1995;8:331-3.
20. Sato T, Matsubara O, Tanaka Y, et al. Association of Sjögren syndrome with pulmonary hypertension: report of two cases and review of the literature. Hum Pathol 1993;24:199-205.
21. Asherson RA, Cervera R. Review: antiphospholipid antibodies and the lung. J Rheumatol 1995;22:62-6.
22. Khamashta MA, Cuadraro MJ, Mujic F, et al. The management of thrombosis in the antiphospholipid antibody syndrome. N Engl J Med 1995;332:993-7.
23. Yeo PPB, Sinniah R. Lupus cor pulmonale with electron micoscope and immunofluorescent antibody studies. Ann Rheum Dis 1975;34:457-8.
24. Brentjens J, Ossi E, Albini B, et al. Disseminated immune deposits in lupus erythematosus. Arthritis Rheum 1977;20:962-8.
25. Karmochkine M, Wechsler B, Godeau P, et al. Improvement of severe pulmonary hypertension in a patient with systemic lupus erythematosus. Ann Rheum Dis 1996;55:561-2.
26. Morelli S, Giordano M, De Marzio P, et al. Pulmonary arterial hypertension responsive to immunosuppressive therapy in systemic lupus erythematosus. Lupus 1993;2:367-9.
27. Dahl M, Chalmers A, Wade J, et al. Ten years survival of a patient with advanced pulmonary hypertension and mixed connective tissue disease treated with immunosuppressive therapy. J Rheumatol 1992;19:1807-9.
28. Groen H, Bootsma H, Postma DS, et al. Primary pulmonary hypertension in a patient with systemic lupus erythematosus: partial improvement with cyclophosphamide. J Rheumatol 1993;20:1055-7.
29. Goupille P, Fauchier L, Babuty D, et al. Precapillary pulmonary hypertension dramatically improved with high doses of corticosteroids during systemic lupus erythematosus. J Rheumatol 1994;21:1976-7.
30. Gallerani M, Govoni M, Ricci L, et al. A 49-year-old woman with dyspnea, palpitations and syncope. Int J Cardiol 1996;55:67-78.
31. Rubin LJ. Primary pulmonary hypertension. N Engl J Med 1997;336:111-7.
32. Hosoda Y, Suzuki Y, Takano M, et al. Mixed connective tissue disease with pulmonary hypertension: a clinical and pathological study. J Rheumatol 1987;14:826-30.
33. Brundage BH. Pulmonary hypertension in collagen vascular disease. In: Fishman A, ed. The pulmonary circulation. Philadelphia: University of Pennsylvania Press, 1990:353-8.
34. Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med 1987;107:216-23.
35. Brenot F. Primary pulmonary hypertension. Case series from France. Chest 1994;105:33-6S.
36. Fahey PJ, Utell MJ, Condemi JJ, et al. Raynaud's phenomenon of the lung. Am J Med 1984;76:263-9.
37. Sitbon O, Brenot F, Denjean A, et al. Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension. Am J Respir Crit Care Med 1995;151:384-9.
38. Sitbon O, Humbert M, Jagot JL, et al. Inhaled nitric oxide as a screening agent to safely identify responders to oral calcium-channel blockers in primary pulmonary hypertension. Eur Respir J 1998;12:265-70.
39. Williamson DJ, Hayward C, Rogers P, et al. Acute hemodynamic responses to inhaled nitric oxide in patients with limited scleroderma and isolated pulmonary hypertension. Circulation 1996;94:477-82.
40. Sanchez O, Sitbon O, Humbert M, et al. Acute hemodynamic responses to vasodilators in patients with connective tissue diseases and pulmonary hypertension. Eur Respir 1998;12:428S.
41. Jolliet P, Thorens JB, Chevrolet JC. Pulmonary vascular reactivity in severe pulmonary hypertension associated with mixed connective tissue disease. Thorax 1995;50:96-7.
42. Ocken S, Reinitz E, Strom J. Nifedipine treatment for pulmonary hypertension in a patient with systemic sclerosis. Arthritis Rheum 1983;26:794-6.
43. Glickson M, Pollack A, Dresner-Feigin R, et al. Nifedipine and prazosin in the management of pulmonary hypertension in CREST syndrome. Chest 1990;98:759-61.
44. Shinohara S, Murata I, Yamada H, et al. Combined effects of diltiazem and oxygen in pulmonary hypertension of mixed connective tissue disease. J Rheumatol 1994;21:1763-5.
45. O'Brien JT, Hill JA, Pepine CJ. Sustained benefit of verapamil in pulmonary hypertension with progressive systemic sclerosis. Am Heart J 1985;109:380-2.
46. Alpert MA, Pressly TA, Mukerji V, et al. Acute and long term effects of nifedipine on pulmonary and systemic hemodynamics in patients with pulmonary hypertension associated with diffuse systemic sclerosis, the CREST syndrome and mixed connective tissue disease. Am J Cardiol 1991;68:1687-91.
47. Niarchos AP, Whitman HH, Goldstein JE, et al. Hemodynamic effects of captopril in pulmonary hypertension of collagen vascular disease. Am Heart J 1982;104:834-8.
48. Alpert MA, Pressly TA, Mukerji V, et al. Short and long-term hemodynamic effects of captopril in patients with pulmonary hypertension and selected connective tissue disease. Chest 1992;102:1407-12.
49. Rubin LJ, Groves BM, Reeves JT, et al. Prostacyclin induced acute pulmonary vasodilation in primary pulmonary hypertension. Circulation 1982;66:334-8.
50. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996;334:296-301.
51. McLaughlin VV, Genthner DE, Panella MM, et al. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med 1998;338:273-7.
52. De La Mata J, Gomez-Sanchez MA, Aranzana M, et al. Long-term iloprost infusion therapy for severe pulmonary hypertension in patients with connective tissue diseases. Arthritis Rheum 1994;37:1528-33.
53. Humbert M, Sanchez O, Fartoukh M, et al. Treatment of severe pulmonary hypertension secondary to connective tissue diseases with continuous intravenous epoprostenol (prostacyclin). Chest 1998;114:80-2S.
54. Seibold JR, Molony RR, Turkevich D, et al. Acute hemodynamic effects of ketanserin in pulmorary hypertension secondary to systemic sclerosis. J Rheumatol 1987;14:519-24.
55. Levine SM, Gibbons WJ, Bryan CL, et al. Single lung transplantation for primary pulmonary hypertension. Chest 1990;98:1107-15.
56. Reitz BA, Wallwork JL, Hunt SA, et al. Heart-lung transplantation: successful therapy for patients with pulmonary vascular disease. N Engl J Med 1982;306:557-64.
57. Levy RD, Guerraty AJ, Yacoub MH, et al. Prolonged survival after heart-lung transplantation in systemic lupus erythematosus. Chest 1993;104:1903-5.
58. Morgan JM, Griffiths M, du Bois RM, et al. Hypoxic pulmonary vasoconstriction in systemic sclerosis and primary pulmonary hypertension. Chest 1991;99:551-6.
59. Humbert M, Sanchez O, Fartoukh M, et al. Short-term and long-term epoprostenol (prostacyclin) therapy in pulmonary hypertension secondary to connective tissue diseases: result of a pilot study. Eur Respir J 1999 (in press).
60. 2): comparison with primary pulmonary hypertension (PPH). Am J Respir Crit Care Med 1999;in press (abstract).